Sotorasib + Lenvatinib
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non Small Cell Lung Cancer
Conditions
Metastatic Non Small Cell Lung Cancer, KRAS G12C
Trial Timeline
Mar 1, 2025 → Dec 30, 2026
NCT ID
NCT06068153About Sotorasib + Lenvatinib
Sotorasib + Lenvatinib is a phase 2 stage product being developed by Eisai for Metastatic Non Small Cell Lung Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06068153. Target conditions include Metastatic Non Small Cell Lung Cancer, KRAS G12C.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non Small Cell Lung Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06068153 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Metastatic Non Small Cell Lung Cancer